EHA25 Virtual Congress

5-year results from that a study on BEGV have confirmed its benefits in classical Hodgkin lymphoma.

Identifying Optimal Immunochemotherapy for Patients With Mantle Cell Lymphoma

Few population-based studies have compared treatment approaches in the setting of mantle cell lymphoma.

Addition of Venetoclax to Azacitidine Associated With Clinically Significant OS Benefit in AML

The addition of venetoclax to azacitidine was associated with a 34% reduction in risk of death.

The phase 3 ADMYRE trial found patients treated with plitidepsin plus dexamethasone had significantl

Addition of Isatuximab to Kd Deepens Responses and Extends PFS in R/R Multiple Myeloma

The majority of patients enrolled in this phase 3 trial had previously received both a proteasome inhibitor and an immunomodulatory agent.

The combination of vorinostat plus bortezomib is active in patients with multiple myeloma who are re

Ropeginterferon Appears to Improve Polycythemia Vera Symptoms

The purpose of this study was to determine if a cytoreductive agent could provide additional efficacy to treat blood hyperviscosity.

Nilotinib in combination with chemotherapy is highly effective in Philadelphia chromosome-, BCR-ALB1

FLT3-ITD With an Insertion Site in the Beta1-Sheet Prognostic for Poor Outcomes in AML

Among adult patients with newly diagnosed AML, the presence of an FLT3-ITD mutation with an insertion site in the beta1-sheet was associated shorter survival.

Results from the phase 3 Myeloma XI trial bolster earlier evidence that maintenance therapy with len

Ixazomib Found Effective as a Maintenance Therapy in Patients With Newly Diagnosed MM Who Are Ineligible for Transplant

Ixazomib maintenance therapy prolonged PFS compared with placebo among patients with newly diagnosed MM who were not eligible for transplant.

Characteristics of Ruxolitinib Discontinuation Syndrome in Myelofibrosis

Ruxolitinib discontinuation syndrome was associated with spleen length and platelet count, although severe cases were rare in a cohort of patients with myelofibrosis.

Overall Survival Improved After Fewer Chemotherapy Cycles in Advanced Hodgkin Lymphoma: Long-Term Follow-Up of GHSG HD18 Trial

Researchers presented findings of a significantly higher 5-year OS rate in patients who received 4 cycles of eBEACOPP compared with patients who received 6/8 cycles.

Immune checkpoint inhibitors may be effective for treating elderly patients with melanoma without dr

Real World Evidence Shows OS Improvements in Older Patients With AML From 2000 to 2016

A population-based study included nearly 4000 patients diagnosed with AML from 2000 to 2016 in Denmark.

Similar ORR was reported for patients regardless of prior exposure to brentuximab vedotin (BV).

Timing of MD-MTX Prophylaxis for DLBCL CNS Relapse Evaluated

Administering MD-MTX prophylaxis against CNS relapse of DLBCL appeared best as early as possible or following R-CHOP completion.

Managing adverse effects after starting a TKI can be challenging, and health care practitioners ofte

Study Provides Support for TKI Discontinuation in Some Patients With CML

This population-based study of patients with chronic phase CML evaluated the BCR/ABL1 TKI discontinuation rates for patients treated on and off a clinical trial.

This fact sheet discusses the importance of palliative care as it pertains to cancer survivorship.

Treatment Modifications Common Among Older Patients With cHL

Modifications of ABVD or CHOP were common among elderly patients with cHL and may contribute to their disproportionate excess mortality, signaling a need for less toxic regimens.

CD-19 targeted 19-28z chimeric antigen receptor-modified T cells induced a complete response rate in

Chemotherapy-Free Regimen Consisting of 3 Novel Agents for Previously Untreated, Poor Prognosis CLL

In this study, obinutuzumab, ibrutinib, and venoclax were administered as first-line therapy in patients with CLL characterized by del(17p) and/or TP53 mutation.

Multiple myeloma specilaists are increasingly transplanting older adults based on performance status and other objective measures of health vs age alone.

All Oral Proteasome Inhibitor-Containing Regimen in Transplant-Ineligible Multiple Myeloma

Ixazomib, lenalidomide, and dexamethasone are all oral agents and each one has been approved by the FDA in the setting of multiple myeloma.

Peripheral blood sample MRD assessment will likely come into routine clinical use in the next few years, according to an expert who specializes in CLL.

Venetoclax Plus Low-Dose Cytarabine Improved OS in Untreated AML Ineligible for Intense Chemotherapy

In an updated analysis, venetoclax plus low-dose cytarabine improved OS compared with placebo among patients with untreated AML who were ineligible for intense chemotherapy.

Pembrolizumab may be an effective treatment for patients with a rare subtype of diffuse large B-cell

Inotuzumab Ozogamicin Plus R-CVP for Patients With DLBCL Who Are Ineligible for R-CHOP

Inotuzumab ozogamicin instead of gemcitabine added to R-CVP did not improve OS or PFS, but less toxicity among patients with untreated DLBCL with comorbid conditions.

Pembrolizumab improved PFS in this high-risk patient population, but a randomized controlled trial is warranted.

Dasatinib-Containing Induction Therapy Associated With High Rates of Allogeneic HSCT in Newly Diagnosed Ph+ ALL

This analysis focused on the allo-HSCT-related end points in a study of patients with newly diagnosed Ph+ ALL treated with a 2-step dasatinib-containing induction regimen.